Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target proteins involved in immune cell maturation and function. The company’s lead candidate, soquelitinib (CPI-818), is a selective covalent ITK inhibitor being evaluated in a multi-center Phase 1b/2 study for several conditions, including peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, solid tumors as monotherapy, and asthma. Corvus is also advancing ciforadenant (CPI-444), an oral A2A receptor antagonist in Phase 2 testing for first-line renal cell cancer, and mupadolimab (CPI-006), a humanized monoclonal antibody in Phase 1 development for non-small cell lung cancer. In addition, the company has licensing agreements with Monash University, Vernalis (R&D) Limited, and Scripps related to antibodies and adenosine receptor antagonists. Corvus Pharmaceuticals was incorporated in 2014 and is based in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CRVS
|
$12.55
|
-12.8% Downside
|
Fair
|
$33.33
|
131.6% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-27.5x
|
5.0x
|
—
|
1.186 B
|
968.7 M
|
0.1%
|
86.5%
|
54.9
|
—
|
79.6%
|
